Pharmaceutical Industry in the
Canton of Ticino

Bioggio Pharma Manufacture SA

Since 1973 · 51–100 empl.

Bioggio Pharma Manufacture SA is a contract development and manufacturing organisation for pharmaceutical and nutraceutical products. The company provides services across design, development and delivery, as well as private label solutions and manufacturing support.

Evultis SA

Since 1978 · 1–10 empl.

The core activity of Evultis SA encompasses the development, manufacturing and distribution of products for the healthcare industry, including: active pharmaceutical ingredients (APIs) and intermediates; pharmaceuticals; dietary supplements (nutraceuticals); cosmetics; veterinary medicines; feed and feed additives; and pet food supplements. The company offers these products for human and animal health and invests in research and development to create innovative solutions for the healthcare industry.

Kamfarma SA

Since 1978 · 11–20 empl.

The core activity of Kamfarma is the development and manufacturing of pharmaceutical active ingredients (APIs) and finished dosage forms (FDFs) in cooperation with global marketing partners. The company specializes in the development of complex generics and innovative medicines, particularly in the areas of oncology and specialized medicines. Kamfarma offers services such as API development, manufacturing and project management, as well as the development of finished dosage forms in various formulations. In addition, the company supports its partners in the clinical development, registration and marketing of medicines in various territories.

Cerbios-Pharma SA

Since 1979 · 51–100 empl.

The core activity of Cerbios-Pharma SA is the development and manufacturing of pharmaceutical active ingredients (APIs), in particular highly potent active ingredients (HPAPIs), antibody-drug conjugates (ADCs) and biologics, as a Contract Development and Manufacturing Organization (CDMO).

Fordras SA

Since 1983 · 101–500 empl.

The company's core activity is the development, production and marketing of natural proteins and enzymes for the food, pharmaceutical and feed industries. The company focuses particularly on the production of highly concentrated, active ingredients for industrial applications, such as lysozymes, and offers solutions for food processing and preservation as well as for the health and nutrition industry.

Chemo Project SA

Since 1984 · 21–50 empl.

The core activity of Insud Pharma is the development, manufacture and marketing of pharmaceutical products. The company operates in the healthcare sector and offers innovative solutions for healthcare. The core activities include research and development (15 research and development centers), production (20 industrial facilities) and distribution of medicines.

Altergon SA

Since 1985 · 1–10 empl.

The core activity of Altergon Italia Srl Unipersonale is the development, manufacture and marketing of pharmaceutical products and medical devices, particularly: * Production of medicated plasters (cerotti medicati) and transdermal patches (patch transdermici) * Production of hydrogel products for topical and transdermal application of active ingredients * Production of hyaluronic acid products (Acido Ialuronico) for the pharmaceutical and medical industry * Development and production of biotechnological products, such as biopolymers for orthopedics and tissue engineering * Production of medical devices, such as pre-filled syringes and infusion solutions * Development and production of innovative products, such as microneedles for transdermal application of active ingredients The company also offers services such as Contract Development and Manufacturing (CDMO), where it takes over the development and production of pharmaceutical products for other companies.

Zambon Switzerland Ltd

Since 1987 · 21–50 empl.

The core activity of Zambon is the development, manufacture and marketing of pharmaceuticals.

VB Technochemicals SA

Since 1993 · 1–10 empl.

The core activity of VB Technochemicals SA encompasses the development, production and distribution of chemical and pharmaceutical products, particularly barium and zinc derivatives, as well as the manufacture of pharmaceutical solutions for various therapeutic areas. The company also provides distribution, marketing and regulatory services.

Osmopharm SA

Since 1994 · 1–10 empl.

The core activity of Osmopharm SA is the development and production of modified oral dosage forms, particularly in pellet, tablet or resin form, using advanced galenic technologies such as coating, extrusion-spheronization and ion exchange. The company also offers services such as the manufacture of hard gelatin capsules or tablets, capsule filling and packaging of pharmaceuticals. Additionally, Osmopharm supports its customers in preparing registration applications and conducting regulatory activities.

Refarmed Chemicals SA

Since 1995 · 21–50 empl.

The core activity of Refarmed Chemicals Ltd. is the distribution of pharmaceutical active ingredients (Active Pharmaceutical Ingredients, API) and finished dosage forms (Finished Dosage Form, FDF) for the generic pharmaceutical industry.

Polichem SA, Lussemburgo, succursale di Mendrisio

Since 1997 · 11–20 empl.

The core activity of Polichem is the research, development, manufacture and marketing of pharmaceutical products, particularly in the fields of dermatology, gynaecology, respiratory diseases and dermocosmetics. The company develops and distributes innovative medicines and products to improve the health of patients worldwide.

Inceptua SA, Luxembourg, Succursale di Bioggio

Since 1997 · 1–10 empl.

Inceptua SA, Luxembourg, Succursale di Bioggio is part of the Inceptua Group and provides pharmaceutical services. Its activities include clinical trial supply (medicines and ancillaries), packaging and labelling, storage and distribution, and the design and implementation of early‑access and unlicensed medicines programmes.

PharmaCina - DHAO SA

Since 2000 · 1–10 empl.

The core activity of PharmaCina DHAO SA is the manufacture and distribution of traditional Chinese medicine products. The company operates a laboratory where it prepares magistral preparations and offers these products through its website and possibly through other distribution channels.

NOVELTY PHARMA GALENICAL DEVELOPMENT AND DOCUMENTATION SA

Since 2003 · 11–20 empl.

The core activity of Novelty Pharma is the production of customer-specific, tailor-made effervescent tablets.

NANONICA SA

Since 2006 · 1–10 empl.

NANONICA SA is a firm focused on knowledge transfer and commercialization of academic research in nanotechnology and microtechnology. It provides advisory services to identify projects and expertise, and supports development and market introduction of technologies across medicine, energy and environmental science.

Walter Pierpaoli Sagl

Since 2006 · 11–20 empl.

The core activity of Pierpaoli Exelyas Srl is the development and production of products based on the research and findings of Professor Walter Pierpaoli, particularly in the field of Neuro-Endocrino-Immuno-Modulation (NEIM) and the regulation of biological rhythms through melatonin. The products aim to promote the body's biological balance, slow down aging and maintain health.

CHEMO AG, Vienna, Lugano Branch

Since 2006 · 1–10 empl.

The core activity of Chemo is the development, manufacture and marketing of pharmaceutical products, including: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs) for human and veterinary use, Over-the-counter (OTC) products, and Dietary supplements and medical devices. The company also offers Contract Manufacturing (CMO) services and has a global presence with 15 manufacturing sites and 200 scientists and researchers.

Lallemand Pharma AG

Since 2007 · 11–20 empl.

The core activity of Lallemand Pharma is the development and marketing of respiratory products classified as medicinal products or medical devices. In particular, the company focuses on the manufacture of immunostimulant drugs and medical devices based on bacterial lysates such as PMBL.

CoreQuest Sagl

Since 2008 · 1–10 empl.

CoreQuest Sagl is a pharmaceutical company conducting research and development of pharmaceutical products and medical devices in nephrology and surgical areas. It develops biocompatible hypertonic solutions for peritoneal dialysis, designs devices and monitoring techniques for dialysis patients, and pursues research programs addressing chronic renal failure and congestive heart failure, including a peritoneal ultrafiltration platform (Polycore).

ROELMI HPC SWISS SA

Since 2008 · 1–10 empl.

ROELMI HPC SWISS SA develops and markets ingredients and functional solutions for the health, personal care and nutraceutical markets. The company offers an ingredient portfolio, formulation support and application-oriented solutions for cosmetics and nutrition-related uses.

Humabs BioMed SA

Since 2011 · 11–20 empl.

The core activity of Humabs BioMed SA is the discovery and development of anti-infective immunotherapies for the treatment of viral and bacterial diseases, including those caused by Zika, Ebola, Rabies, Dengue and other Flaviviruses. The company focuses on the development of therapeutics up to clinical proof of concept and has a broad pipeline of development candidates.

Valentis AG

Since 2011 · 101–500 empl.

The core activity of Valentis is the development, production and distribution of natural medical products, including dietary supplements, plant-based products, medical devices and liquid nutraceuticals, with a focus on nanotechnology. The company also offers contract manufacturing and private label production for other companies.

Swiss Applied Coating Research (S.A.C.R.) GmbH

Since 2011 · 1–10 empl.

The core activity of Swiss A.C.R. Applied Coating Research is the development and production of film coating solutions for the pharmaceutical, nutraceutical and food industries, with a particular focus on natural polymers. The company offers specialized services such as the development of Solid Oral Dosage Forms, Colon-Delivery and Sustained-Release systems, as well as the provision of natural functional polymers for coatings.

MABXIENCE SA

Since 2012 · 101–500 empl.

The company's core activity is the development, manufacture and marketing of biopharmaceutical products, including active pharmaceutical ingredients (APIs), vaccines and finished dosage forms (FDFs), as well as the production of biotechnological medicines for the manufacture of monoclonal antibodies and vaccines.

ADIENNE SA

Since 2012 · 21–50 empl.

ADIENNE SA is an integrated biopharmaceutical group focused on research, development and manufacturing of medicines for rare and severe hematological and immunological diseases. The company provides GMP development and manufacturing services, including lyophilization of cytotoxic finished products in ready-to-use systems (e.g., Multichamber Flexible Bag, FillChoice), and markets products such as TEPADINA® and PHELINUN®.

Cures Healthcare Ltd

Since 2012 · 11–20 empl.

The core activity of Cures Health Care is the development, manufacture and export of pharmaceutical products, particularly generics and biosimilars, of both Swiss and non-Swiss origin. The company offers a wide range of medications, including tablets, capsules and injectable products, used to treat various diseases and conditions, such as hypertension, diabetes, anxiety disorders and cancer. Cures Health Care operates in over 12 countries worldwide, including the MENA region, Europe, the US and Canada, and collaborates with local licensees and government authorities to offer its products on the respective markets.

Seegpharm SA

Since 2012 · 1–10 empl.

Seegpharm SA develops and out-licenses complex generic pharmaceuticals through product co‑development. The company outsources development work including API synthesis‑route development and finished‑dosage‑form development, manages patent freedom‑to‑operate analyses and regulatory registrations, and undertakes selected promotion and distribution activities.

Fondazione Ceschina

Since 2013 · 1–10 empl.

The core activity of Sanitaria Ceschina & C. (S.p.A.) is the manufacture and distribution of medical products, particularly aseptic and antiseptic medications as well as health equipment.

H.E. ADVANCED NUTRITION SA

Since 2013 · 11–20 empl.

The core activity of HE Advanced Nutrition SA is the research and production of nutraceutical and pharmaceutical products, particularly food supplements and medicines, with innovative formulations and the highest quality standards.

ADIENNE Pharma & Biotech SA

Since 2013 · 101–500 empl.

ADIENNE Pharma & Biotech SA is an integrated biopharmaceutical group that develops medicinal products and provides pharmaceutical and biotech manufacturing services. The company focuses on rare hematological and immunological diseases, maintains a portfolio of orphan-designated, marketed, clinical and preclinical product candidates, offers lyophilization for cytotoxic products in ready-to-use systems, and its lead clinical candidate is BEGELOMAB.

PHARMA TICINO SA

Since 2014 · 1–10 empl.

The core activity of Pharmaticino SA is to advise and support pharmaceutical companies in the development and marketing of medicines, particularly in the region south of the Alps. This also includes providing services in the healthcare sector, such as setting up medical studies, fitness and pharmacy offers.

MAS pharma SA

Since 2015 · 1–10 empl.

MAS pharma SA operates a pharmacy focused on biomedicine and offers related services in functional medicine, therapeutic care, clinical analyses and compounding. Its range also includes orthopedic advice, nutrition, relaxation techniques, veterinary advice, a postal counter and a minimarket.

Cronet Sagl

Since 2015 · 1–10 empl.

The core activity of Cronet Sagl is consulting and project management for pharmaceutical research and development projects (R&D). The company supports customers in the development of medicinal products and medical devices by leveraging its long-standing experience and collaboration with international laboratories and experts. The services include project and study planning, selection and monitoring of Contract Research Organizations (CRO), document review, support in approval procedures and communication with regulatory authorities.

PHARGENTIS SA

Since 2015 · 11–20 empl.

The core activity of Phargentis SA is the virtual development of pharmaceuticals, in particular the development of complex dosage forms for generics and innovative SuperGenerics products, as well as the licensing of these products to leading pharmaceutical companies worldwide.

MADDOX Pharma Swiss GmbH

Since 2015 · 1–10 empl.

The core activity of Maddox Pharma Swiss is the development, manufacture and marketing of health products, particularly pharmaceuticals and dietary supplements, with the aim of improving people's quality of life and creating stakeholder value.

GT Gain Therapeutics SA

Since 2017 · 11–20 empl.

The company is active in the field of biopharmaceuticals (bio-pharma).

PROBIONOVA SA

Since 2018 · 11–20 empl.

The core activity of Probionova SA is the research and development of new probiotic strains and applications for therapeutic purposes, particularly in the field of human health and microbiome. The company develops clinically evidence-based probiotics with pharmaceutical quality for therapeutic applications and offers services such as the selection and development of probiotic strains, the manufacture of probiotic combinations, and the provision of full-service solutions.